BIRC5 and acute myeloid leukemia: In AML patients, survivin is an indicator of poor prognosis, associated with drug resistance, and it is overexpressed in the leukemic stem cell (LSC) population compared to the leukemic population, making it a promising target for down-regulation [37,38].